Novo Nordisk A/S
NOVO-B
Peringkat dalam Saham
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Harga Saham
$39.74
Kapitalisasi Pasar
$175.38B
Perubahan (1 hari)
1.28%
Perubahan (1 tahun)
-25.58%
Negara
DK
Perdagangan Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
Rasio P/E untuk Novo Nordisk A/S (NOVO-B)
Rasio P/E per October 2026 TTM: 10.10
Menurut laporan keuangan dan harga saham terbaru dari Novo Nordisk A/S, rasio P/E saat ini (TTM) adalah 10.10. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 27.53.
Riwayat rasio P/E untuk Novo Nordisk A/S dari 2001 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 10.10 | -28.39% |
| 2025 | 14.10 | -48.77% |
| 2024 | 27.53 | -26.39% |
| 2023 | 37.40 | -2.28% |
| 2022 | 38.27 | 8.25% |
| 2021 | 35.35 | 49.61% |
| 2020 | 23.63 | 0.26% |
| 2019 | 23.57 | 23.65% |
| 2018 | 19.06 | -12.01% |
| 2017 | 21.66 | 27.49% |
| 2016 | 16.99 | -42.39% |
| 2015 | 29.49 | 14.43% |
| 2014 | 25.77 | 21.85% |
| 2013 | 21.15 | -11.44% |
| 2012 | 23.88 | 9.42% |
| 2011 | 21.83 | -13.90% |
| 2010 | 25.35 | 37.23% |
| 2009 | 18.48 | 6.65% |
| 2008 | 17.32 | -27.90% |
| 2007 | 24.03 | 1.28% |
| 2006 | 23.72 | 19.31% |
| 2005 | 19.88 | -0.71% |
| 2004 | 20.02 | 18.71% |
| 2003 | 16.87 | -2.64% |
| 2002 | 17.33 | -43.27% |
| 2001 | 30.54 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 43.73 | 333.08% |
US
|
|
| 39.77 | 293.86% |
US
|
|
| 80.21 | 694.41% |
US
|
|
| 121.17 | 1,099.99% |
US
|
|
| 25.53 | 152.81% |
CH
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.